Effect of NMN on ovarian reserve issues
Effect of NMN (Nicotinamide Mononucleotide) Intervention on Patients With Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency)
This study is testing if a supplement called NMN can help women with low ovarian reserve, including those with early menopause, improve their reproductive health and outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 20 Years to 40 Years |
| Sex | Female |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05485610 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of nicotinamide mononucleotide (NMN) on women experiencing diminished ovarian reserve, including those with premature ovarian insufficiency. It aims to assess NMN's effects on reproductive endocrine function, immune homeostasis, and reproductive outcomes. The study will also investigate the underlying mechanisms of NMN to develop intervention strategies for these conditions.
Who should consider this trial
Good fit: Ideal candidates are women aged 20 to 40 with specific hormonal and follicle count criteria indicating diminished ovarian reserve.
Not a fit: Patients who are pregnant, lactating, or menopausal, as well as those with certain genetic conditions or chronic diseases requiring regular medication, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for women with diminished ovarian reserve, potentially improving their reproductive health.
How similar studies have performed: While the use of NMN is a relatively novel approach in this context, similar studies exploring its effects on metabolic and reproductive health have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals who are 20 to 40 years old. 2. The concentrations of anti-Mullerian hormone \< 1.1 ng/ml, the values of antral follicle count range from less than 5 to less than 7 and two recordings of serum concentrations of day-3 follicle-stimulating hormone (FSH) ≥10 IU/L. 3. Individuals who can insist on continuous monitoring in the outpatient clinic. 4. Individuals who are not participating in other research projects currently or 3 months before the intervention. Exclusion Criteria: 1. Individuals who are during pregnant, lactation or menopause. 2. Individuals who had non-46-XX karyotype, or attributed to known genetic etiology. 3. Individuals who had pelvic surgery. 4. Cancer patients or receiving chemo/radiotherapy treatment within the past 5 years. 5. Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc. 6. Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months. 7. Use of medications or traditional Chinese medicine that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 3 months. 8. Individuals who take niacin, nicotinamide, or other vitamin B3-related supplementation, or other supplementation such as coenzyme Q10, vitamin E currently or within the past 3 months. 9. Use of antibiotics, probiotics, or prebiotics that affect the flora within the past 3 months. 10. Individuals with severe liver diseases or kidney disease that are ineligible to participate in the study. 11. A medical history of severe cardiovascular and cerebrovascular diseases. 12. Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption. 13. Individuals who drink more than 15g of alcohol per day or have a smoking habit. 14. Individuals who need drug treatment for any mental illness such as epilepsy and depression. 15. Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc. 16. Unable or unwilling to follow the study protocol.
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.